Update: pneumococcal polysaccharide vaccine
IRR, incidence rate ratio; PPV23-13, 23- valent pneumococcal polysaccharide vaccine
serotype cases, excluding those also contained in the 13-valent pneumococcal conjugate vaccine; NVT, nonvaccine type serotype cases.
Cheesman et al., "Maternal immunization with pneumococcal polysaccharide vaccine
in the third trimester of gestation," Vaccine, vol.
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
. N Engl J Med 1991; 325:1453.
Starting August 5, the seasonal influenza and pneumococcal polysaccharide vaccines
will be available at all 32 primary healthcare centres of Seha's Ambulatory Healthcare Services (AHS).
pneumoniae or pneumococcal polysaccharide vaccines
. Uddin et al.
Conversely, the 23-valent pneumococcal polysaccharide vaccine
(PPSV23) showed limited effectiveness against serotypes unique to that vaccine in the study, which included 699 cases and more than 10,000 controls, Olivia Almendares, an epidemiologist at the Centers for Disease Control and Prevention, Atlanta, and her colleagues reported at the International Conference on Emerging Infectious Diseases.
This vaccine is available in two types: PCV or PCV 13 pneumococcal conjugate vaccine; and PPSV or PPSV 23 pneumococcal polysaccharide vaccine
This FDA's decision to approve the label expansion is based on the submission and review of data from the company's open-label, Phase 3 trial of Prevnar 13 in adults who were not previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine
Another noteworthy change is in the amount of time recommended between receiving the 13-valent pneumococcal conjugate vaccine (PCV13) and the subsequent 23-valent pneumococcal polysaccharide vaccine
(PPSV23) in adults aged 65 years and older who are deemed "immunocompetent."
* Interval change for 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine
(PPSV23) from "6 to 12 months" to "at least 1 year" for adults aged [greater than or equal to] 65 years who do not have immunocompromising conditions, anatomical or functional asplenia, cerebrospinal fluid leaks, or cochlear implants (1).
In addition, the analysis showed that 59% of disease among adults 18-64 years of age occurred in persons who had an indication for receiving 23-valent pneumococcal polysaccharide vaccine